# Aceragen

Aceragen is an Asset Manager based in United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** United States
- **Region:** North America
- **Address:** United States
- **Assets under management:** Undisclosed
- **Website:** aceragen.com
- **LinkedIn:** https://www.linkedin.com/company/aceragen

## Regulatory record

- **Reports private funds:** No

## About

Aceragen is a biotechnology firm based in Durham, United States, established in 2021. It focuses on developing treatments for rare and ultra-rare diseases. The company has secured $35 million in total funding.

## Sectors

- Biotech
- Therapeutics
- Rare Diseases

## Questions

### What is Aceragen's primary therapeutic focus?

Aceragen concentrates on rare pulmonary and infectious diseases, particularly acute respiratory distress syndrome (ARDS) and chronic gram-negative lung infections. Its lead programs use inhaled biologic delivery to target the lung directly (per the firm's pipeline disclosures).

### What is ACG-201, and what is its intended use?

ACG-201 is Aceragen's lead candidate — an inhaled angiotensin-converting enzyme 2 (ACE2) fusion protein designed for ARDS. It aims to reduce inflammation and protect lung tissue by binding to SARS-CoV-2 spike protein and other inflammatory mediators (per firm materials, 2023).

### How was Aceragen formed?

Aceragen was created via merger in 2020, combining Synspira Therapeutics (focused on CFTR modulators) with Aceragen Therapeutics (focused on ACE2 fusion proteins, per SEC filings, 2020). The corporate history is not extensively documented beyond this transaction.

### Who are the key executives or founders at Aceragen?

Publicly available sources do not name a CEO, board members, or founding team for Aceragen. The firm maintains a low profile and does not prominently disclose leadership on its website as of late 2024.

### What stage of development are Aceragen's pipeline candidates in?

ACG-201 advanced to Phase 2 trials targeting ARDS, while ACG-301 remains in preclinical development. The firm's CFTR-related programs were inherited from Synspira and are less advanced (per the firm's pipeline updates, 2023).

### How does Aceragen differentiate its platform from other biotech firms?

Aceragen's key differentiator is its inhaled biologic delivery technology, which delivers large protein therapeutics directly to the lung. This approach aims to reduce systemic side effects while concentrating the drug at the site of disease for pulmonary indications.

## Related profiles

- [Stonewall Kitchen](https://altss.com/profile/stonewall-kitchen)
- [Virginia Biosciences Health Research Corporation](https://altss.com/profile/virginia-biosciences-health-research-corporation)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/aceragen

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology